Severe Combined Immunodeficiency (SCID) Overview

Save information for later
Sign Up

Learn About Severe Combined Immunodeficiency (SCID)

What is the definition of Severe Combined Immunodeficiency (SCID)?
Severe combined immunodeficiencies (SCID) are inherited immune system disorders characterized by abnormalities with responses of both T cells and B cells (specific types of white blood cells needed for immune system function). Common signs and symptoms include an increased susceptibility to infections including ear infections; pneumonia or bronchitis; oral thrush; and diarrhea. Due to recurrent infections, children with SCID do not grow and gain weight as expected (failure to thrive). SCID may be caused by genetic changes in any of several genes and can be inherited in an X-linked recessive (most commonly) or autosomal recessive manner. The most common type of SCID is called X-linked Severe combined immunodeficiency (XSCID). Another form of SCID is caused by a deficiency of the enzyme adenosine deaminase (ADA).
What are the alternative names for Severe Combined Immunodeficiency (SCID)?
  • Severe combined immunodeficiency
  • SCID
Who are the top Severe Combined Immunodeficiency (SCID) Local Doctors?
Elite in Severe Combined Immunodeficiency (SCID)
Dr. Robert A. Sokolic
Hematology Oncology | Hematology | Oncology
Elite in Severe Combined Immunodeficiency (SCID)
Dr. Robert A. Sokolic
Hematology Oncology | Hematology | Oncology
593 Eddy St, 
Providence, RI 
401-444-5391
Languages Spoken:
English
See accepted insurances

Robert Sokolic is a Hematologist Oncology specialist and a Hematologist in Providence, Rhode Island. Dr. Sokolic is rated as an Elite provider by MediFind in the treatment of Severe Combined Immunodeficiency (SCID). His top areas of expertise are Severe Combined Immunodeficiency (SCID), Adenosine Deaminase Deficiency, Chronic B-Cell Leukemia (CBCL), Sickle Cell Disease, and Bone Marrow Transplant.

Andrew R. Gennery
Elite in Severe Combined Immunodeficiency (SCID)
Andrew R. Gennery
Elite in Severe Combined Immunodeficiency (SCID)
Andrew R. Gennery
Queen Victoria Road, 
Newcastle Upon Tyne, ENG, GB 

Andrew Gennery practices in Newcastle Upon Tyne, United Kingdom. Mr. Gennery is rated as an Elite expert by MediFind in the treatment of Severe Combined Immunodeficiency (SCID). His top areas of expertise are Primary Immunodeficiency (PID), Severe Combined Immunodeficiency (SCID), Chronic Granulomatous Disease, Bone Marrow Transplant, and Heart Transplant.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Severe Combined Immunodeficiency (SCID)
Dr. Christopher C. Dvorak
Pediatric Hematology Oncology
Elite in Severe Combined Immunodeficiency (SCID)
Dr. Christopher C. Dvorak
Pediatric Hematology Oncology
725 Welch Rd, 
Palo Alto, CA 
650-723-4000
Languages Spoken:
English
See accepted insurances

Christopher Dvorak is a Pediatric Hematologist Oncology provider in Palo Alto, California. Dr. Dvorak is rated as an Elite provider by MediFind in the treatment of Severe Combined Immunodeficiency (SCID). His top areas of expertise are Severe Combined Immunodeficiency (SCID), Juvenile Myelomonocytic Leukemia (JMML), Hepatic Venoocclusive Disease with Immunodeficiency, Bone Marrow Transplant, and Splenectomy.

View All Doctors
What are the latest Severe Combined Immunodeficiency (SCID) Clinical Trials?
A Phase II Study of Reduced Intensity Conditioning in Pediatric Patients and Young Adults ≤55 Years of Age With Non-Malignant Disorders Undergoing Umbilical Cord Blood, Bone Marrow, or Peripheral Blood Stem Cell Transplantation
A Phase II Study of Reduced Intensity Conditioning in Pediatric Patients and Young Adults ≤55 Years of Age With Non-Malignant Disorders Undergoing Umbilical Cord Blood, Bone Marrow, or Peripheral Blood Stem Cell Transplantation
Who is this study for: Patients with non-malignant disorders that are amenable to treatment with hematopoietic stem cell transplant
Enrollment Status: Recruiting
Publish Date: December 15, 2025
Intervention Type: Drug
Study Drugs: Hydroxyurea, Alemtuzumab, Fludarabine, Melphalan, Thiotepa
Study Phase: Phase 2

Summary: The objective of this study is to evaluate the efficacy of using a reduced-intensity condition (RIC) regimen with umbilical cord blood transplant (UCBT), double cord UCBT, matched unrelated donor (MUD) bone marrow transplant (BMT) or peripheral blood stem cell transplant (PBSCT) in patients with non-malignant disorders that are amenable to treatment with hematopoietic stem cell transplant (HSCT). ...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Who is this study for: Infant male patients with Severe Combined Immunodeficiency
Enrollment Status: Recruiting
Publish Date: December 11, 2025
Intervention Type: Biological
Study Drug: Autologous CD34-Positive G2SCID Vector-Transduced Peripheral Blood Cells
Study Phase: Phase 1/Phase 2

Summary: This is a phase I/II open label multi-center study in which patients will receive low dose targeted busulfan followed by infusion of autologous CD34+ selected bone marrow or mobilized peripheral blood cells transduced with the G2SCID vector. Subjects will be enrolled over 3 years and be followed for 2 years post-infusion on this protocol, then followed long-term on a separate long-term follow-up p...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center